RT Journal
A1 Stratta RJ, Shaefer MS, Markin RS, et al
T1 CLinical patterns of cytomegalovirus disease after liver transplantation
JF Archives of Surgery
JO Archives of Surgery
YR 1989
FD December 1
VO 124
IS 12
SP 1443
OP 1450
DO 10.1001/archsurg.1989.01410120093018
UL http://dx.doi.org/10.1001/archsurg.1989.01410120093018
AB • During a 43-month period, we performed 248 liver transplantations in 211 patients (127 adults and 84 children). Cytomegalovirus (CMV) disease was documented in 73 recipients (34.6%). Risk factors for CMV disease included donor CMV seropositivity, antilymphocyte therapy, and retransplantation. The mean time of occurrence of CMV disease was 38.3 days after transplantation, and the most frequent site of disease was the hepatic allograft. A total of 69 patients were treated with intravenous ganciclovir, with a prompt and lasting response documented in 51 (73.9%). The remaining 18 (26.1%) developed recurrent CMV disease, which was more common after primary CMV exposure. Cytomegalovirus disease was ultimately controlled by ganciclovir in 94.2% of cases. This disease occurs early after transplantation and can be related to well-defined risk factors. Although ganciclovir therapy is effective, preliminary experience with prophylaxis shows promise in reducing the incidence of CMV disease.(Arch Surg. 1989;124:1443-1450)